2026 Q3 -tulosraportti
Vain PDF
71 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,70%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenChemoMetec receives indirect positive support from Johnson & Johnson's Q2 financial report, where the CAR-T treatment CARVYKTI, which is relevant for ChemoMetec's largest customer, delivered sales of USD 657 mio. corresponding to 50 pct.
·1 päivä sittenWhat catalysts does this stock have?
I have high expectations for the annual report on September 10, and so does the market. Here's what I'm following closely and what I believe we will get more answers on in September: XM profitability: does their new cell counter XM generate as much consumable revenue per instrument as the old NC? And are they able to convert existing customers to the new platform? In my opinion, this is the most crucial question for the stock going forward Guiding: there has already been one disappointment in 2026. If they maintain the guiding for September, or even better, raise it, it will be a strong positive signal. If they disappoint again, the stock will be punished very severely Roche LOI: a formal agreement here would, in my opinion, be a significant re-rating of the stock. The company has communicated that the parties are working to concretize the collaboration during 2026. There are six months left of the year… USA: 59% of revenue comes from there. NIH cuts and political unrest have hit hard. I'm monitoring whether the American market normalizes
·2 päivää sittenGive us some news now, so we can move past 400 and up and test 200MA.
You are too eager ⏰ Wait two months for the report, and they show sales have returned 🥂 and then you can wait for collaboration with Roche 🕺 Then you have your price 7-8-900 📈 I bought in at 270-350 and 416, and I have never been so sure about an investment - chemometec are so incredibly good at earning 💰- ·3 päivää sittenWhat is Chemm doing? There are three interesting indirect signals. 1. Competitors are aggressively marketing to HiRes customers The most prominent example is Nova Biomedical, which has created an entire campaign page: “Looking for a Cedex HiRes Replacement?” They even offer a trade-in program and position FAST CDV as the natural successor to HiRes. This tells us that competitors expect HiRes customers to be actively looking for a new solution. 2. Beckman has made specific comparisons against HiRes Beckman has published data directly comparing Vi-CELL BLU with Cedex HiRes. This is classic “migration marketing”. 3. Software vendors continue to support HiRes An interesting finding is that Benchling as late as June 2026 released a new configuration guide for their Cedex HiRes data connector. This does not mean that Benchling expects HiRes to live on. It probably just means that many customers still use HiRes, and therefore need integration until the migration is completed. The most interesting absence For me, it's almost more interesting what isn't found. I have not found: * Roche cases on migration. * Customer cases on migration. * Beckman cases where a named Roche customer says they are switching. * CHEMM cases where a former HiRes customer talks about XM30. So the answer is Chemm isn't doing much to get the HiRes customers. Why not?
clahn1, thanks for the market analysis. ChemoMetec should leverage the situation with Sedex’s phasing out and use simple sample handling and robustness as a selling point. Otherwise, Nova Biomedical risks taking over too large a share of the migration market. - ·9.7.I've been looking at metec for a long time, and am in the process of researching the stock, but find the price difficult to assess. Can anyone here give me a brief idea about future pricing in your eyes and market share etc.? Is it now I should jump on board or will we dip again...? Thanks in advance🙏🏽
I bought in today, after having been a bit back and forth for a while. I am long-term and have cautiously set my expectations for an annual return of approx 10-11% I mainly base this on the expected annual growth, strong management with a solid focus on the business's growth model (the dividend certainly doesn't hurt either, even if it's modest). Of course, the stock might fall further in the short term, but personally, I believe in growth in the long run.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
Vain PDF
71 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,70%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenChemoMetec receives indirect positive support from Johnson & Johnson's Q2 financial report, where the CAR-T treatment CARVYKTI, which is relevant for ChemoMetec's largest customer, delivered sales of USD 657 mio. corresponding to 50 pct.
- ·1 päivä sittenWhat catalysts does this stock have?I have high expectations for the annual report on September 10, and so does the market. Here's what I'm following closely and what I believe we will get more answers on in September: XM profitability: does their new cell counter XM generate as much consumable revenue per instrument as the old NC? And are they able to convert existing customers to the new platform? In my opinion, this is the most crucial question for the stock going forward Guiding: there has already been one disappointment in 2026. If they maintain the guiding for September, or even better, raise it, it will be a strong positive signal. If they disappoint again, the stock will be punished very severely Roche LOI: a formal agreement here would, in my opinion, be a significant re-rating of the stock. The company has communicated that the parties are working to concretize the collaboration during 2026. There are six months left of the year… USA: 59% of revenue comes from there. NIH cuts and political unrest have hit hard. I'm monitoring whether the American market normalizes
- ·2 päivää sittenGive us some news now, so we can move past 400 and up and test 200MA.You are too eager ⏰ Wait two months for the report, and they show sales have returned 🥂 and then you can wait for collaboration with Roche 🕺 Then you have your price 7-8-900 📈 I bought in at 270-350 and 416, and I have never been so sure about an investment - chemometec are so incredibly good at earning 💰
- ·3 päivää sittenWhat is Chemm doing? There are three interesting indirect signals. 1. Competitors are aggressively marketing to HiRes customers The most prominent example is Nova Biomedical, which has created an entire campaign page: “Looking for a Cedex HiRes Replacement?” They even offer a trade-in program and position FAST CDV as the natural successor to HiRes. This tells us that competitors expect HiRes customers to be actively looking for a new solution. 2. Beckman has made specific comparisons against HiRes Beckman has published data directly comparing Vi-CELL BLU with Cedex HiRes. This is classic “migration marketing”. 3. Software vendors continue to support HiRes An interesting finding is that Benchling as late as June 2026 released a new configuration guide for their Cedex HiRes data connector. This does not mean that Benchling expects HiRes to live on. It probably just means that many customers still use HiRes, and therefore need integration until the migration is completed. The most interesting absence For me, it's almost more interesting what isn't found. I have not found: * Roche cases on migration. * Customer cases on migration. * Beckman cases where a named Roche customer says they are switching. * CHEMM cases where a former HiRes customer talks about XM30. So the answer is Chemm isn't doing much to get the HiRes customers. Why not?clahn1, thanks for the market analysis. ChemoMetec should leverage the situation with Sedex’s phasing out and use simple sample handling and robustness as a selling point. Otherwise, Nova Biomedical risks taking over too large a share of the migration market.
- ·9.7.I've been looking at metec for a long time, and am in the process of researching the stock, but find the price difficult to assess. Can anyone here give me a brief idea about future pricing in your eyes and market share etc.? Is it now I should jump on board or will we dip again...? Thanks in advance🙏🏽I bought in today, after having been a bit back and forth for a while. I am long-term and have cautiously set my expectations for an annual return of approx 10-11% I mainly base this on the expected annual growth, strong management with a solid focus on the business's growth model (the dividend certainly doesn't hurt either, even if it's modest). Of course, the stock might fall further in the short term, but personally, I believe in growth in the long run.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
2026 Q3 -tulosraportti
Vain PDF
71 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
7,00 DKK/osake
Viimeisin osinko
1,70%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenChemoMetec receives indirect positive support from Johnson & Johnson's Q2 financial report, where the CAR-T treatment CARVYKTI, which is relevant for ChemoMetec's largest customer, delivered sales of USD 657 mio. corresponding to 50 pct.
- ·1 päivä sittenWhat catalysts does this stock have?I have high expectations for the annual report on September 10, and so does the market. Here's what I'm following closely and what I believe we will get more answers on in September: XM profitability: does their new cell counter XM generate as much consumable revenue per instrument as the old NC? And are they able to convert existing customers to the new platform? In my opinion, this is the most crucial question for the stock going forward Guiding: there has already been one disappointment in 2026. If they maintain the guiding for September, or even better, raise it, it will be a strong positive signal. If they disappoint again, the stock will be punished very severely Roche LOI: a formal agreement here would, in my opinion, be a significant re-rating of the stock. The company has communicated that the parties are working to concretize the collaboration during 2026. There are six months left of the year… USA: 59% of revenue comes from there. NIH cuts and political unrest have hit hard. I'm monitoring whether the American market normalizes
- ·2 päivää sittenGive us some news now, so we can move past 400 and up and test 200MA.You are too eager ⏰ Wait two months for the report, and they show sales have returned 🥂 and then you can wait for collaboration with Roche 🕺 Then you have your price 7-8-900 📈 I bought in at 270-350 and 416, and I have never been so sure about an investment - chemometec are so incredibly good at earning 💰
- ·3 päivää sittenWhat is Chemm doing? There are three interesting indirect signals. 1. Competitors are aggressively marketing to HiRes customers The most prominent example is Nova Biomedical, which has created an entire campaign page: “Looking for a Cedex HiRes Replacement?” They even offer a trade-in program and position FAST CDV as the natural successor to HiRes. This tells us that competitors expect HiRes customers to be actively looking for a new solution. 2. Beckman has made specific comparisons against HiRes Beckman has published data directly comparing Vi-CELL BLU with Cedex HiRes. This is classic “migration marketing”. 3. Software vendors continue to support HiRes An interesting finding is that Benchling as late as June 2026 released a new configuration guide for their Cedex HiRes data connector. This does not mean that Benchling expects HiRes to live on. It probably just means that many customers still use HiRes, and therefore need integration until the migration is completed. The most interesting absence For me, it's almost more interesting what isn't found. I have not found: * Roche cases on migration. * Customer cases on migration. * Beckman cases where a named Roche customer says they are switching. * CHEMM cases where a former HiRes customer talks about XM30. So the answer is Chemm isn't doing much to get the HiRes customers. Why not?clahn1, thanks for the market analysis. ChemoMetec should leverage the situation with Sedex’s phasing out and use simple sample handling and robustness as a selling point. Otherwise, Nova Biomedical risks taking over too large a share of the migration market.
- ·9.7.I've been looking at metec for a long time, and am in the process of researching the stock, but find the price difficult to assess. Can anyone here give me a brief idea about future pricing in your eyes and market share etc.? Is it now I should jump on board or will we dip again...? Thanks in advance🙏🏽I bought in today, after having been a bit back and forth for a while. I am long-term and have cautiously set my expectations for an annual return of approx 10-11% I mainly base this on the expected annual growth, strong management with a solid focus on the business's growth model (the dividend certainly doesn't hurt either, even if it's modest). Of course, the stock might fall further in the short term, but personally, I believe in growth in the long run.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt